Abstract: A vehicle driver warning device includes: a steering angle sensor (SAS) producing steering signals representative of a real time angle of rotation of a steering column (RTARSC), a control unit receiving said signals and generating a timer activation signal (TAS) when an absolute value of the RTARSC is equal to a maximum value and a timer deactivation signal (TDS) when the absolute value is less than the maximum value after being equal to the maximum value, a timer receiving the TAS and starting a preset period of time countdown and interrupting said countdown if the TDS is received before the countdown ends, an alarm module generating an alarm perceptible to the driver upon receiving an alarm activation signal (AAS), wherein the control unit generates and communicates the AAS to the alarm module at the end of the preset period of time if the countdown has not been interrupted.

Abstract: A vehicle driver warning device includes: a steering angle sensor (SAS) producing steering signals representative of a real time angle of rotation of a steering column (RTARSC), a control unit receiving said signals and generating a timer activation signal (TAS) when an absolute value of the RTARSC is equal to a maximum value and a timer deactivation signal (TDS) when the absolute value is less than the maximum value after being equal to the maximum value, a timer receiving the TAS and starting a preset period of time countdown and interrupting said countdown if the TDS is received before the countdown ends, an alarm module generating an alarm perceptible to the driver upon receiving an alarm activation signal (AAS), wherein the control unit generates and communicates the AAS to the alarm module at the end of the preset period of time if the countdown has not been interrupted.

Abstract: An amorphous form of cabazitaxel is disclosed. It is preferably characterized by an X-ray powder diffraction (XRD) pattern as depicted in FIG. 1. It is prepared by (a) preparing a solution of cabazitaxel in a suitable solvent and mixture thereof; and (b) recovering the amorphous forms of cabazitaxel from the solution by removal of the solvent.

Abstract: The present invention provides Crystalline Forms of 4-acetoxy-2?-benzoyloxy-5?-20-epoxy-1-hydroxy-7?,10?-dimethoxy-9-oxotax-11-en-13?-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate, i.e Cabazitaxel. The present invention also discloses methods for the preparation of Crystalline Forms of Cabazitaxel and pharmaceutical compositions thereof.

Abstract: The present invention discloses novel processes for preparing optically active sulphoxide compounds of formula I by asymmetric oxidation of prochiral sulphide compounds of Formula II. More particularly, the invention discloses processes for preparation of optically active proton pump Inhibitors (PPIs) or their optically active precursor (=intermediate) compounds (Formula I) that can be converted into pharmaceutically useful PPIs.